SCHEMBL2581233

SCHEMBL2581233

O=Cc1ccc(C=C(F)F)cc1

nearest known ligand 0.52

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH5A1 P51649 1/20 0.52
ABAT P80404 1/20 0.52
EGFR P00533 2/20 0.52
ALDH1A1 P00352 6/20 0.46
KDM4E B2RXH2 2/20 0.46
CYP2A6 P11509 4/20 0.46
HSD17B10 Q99714 1/20 0.46
TYR P14679 1/20 0.41
PTGS2 P35354 1/20 0.41
RAB9A P51151 1/20 0.41
CYP2A13 Q16696 1/20 0.41
ALDH1A3 P47895 2/20 0.38
ALDH3A1 P30838 1/20 0.38
DRD1 P21728 1/20 0.38
TRIM24 O15164 1/20 0.37
TRIM33 Q9UPN9 1/20 0.37
PARP10 Q53GL7 1/20 0.36
PARP3 Q9Y6F1 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3018995 0.80 EGFR (0.48) ALDH5A1ABATEGFRALDH1A1KDM4E
SCHEMBL3018992 0.80 EGFR (0.48) ALDH5A1ABATEGFRALDH1A1KDM4E
SCHEMBL17288995 0.79 ALDH1A1 (0.33) EGFRALDH1A1KDM4E
SCHEMBL19056940 0.78 TP53 (0.43) EGFRALDH1A1KDM4EPTGS2DRD1
SCHEMBL2283814 0.77 UNG (0.48) ALDH5A1ABATALDH1A1KDM4ECYP2A6
SCHEMBL4956384 0.76 CYP2A6 (0.69) ALDH5A1ABATEGFRALDH1A1KDM4E
SCHEMBL31171 0.76 CYP2A6 (0.69) ALDH5A1ABATEGFRALDH1A1KDM4E
SCHEMBL3752963 0.76 ESR1 (0.54) ALDH5A1ABATALDH1A1KDM4EHSD17B10
SCHEMBL29043044 0.76 FBP1 (0.47) ALDH1A1PTGS2
SCHEMBL17288775 0.74 ESR1 (0.41) ALDH1A1KDM4EHSD17B10PTGS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8048897-B2 Cyclohexane derivative, prodrug thereof and salt thereof, and therapeutic agent containing the same for diabetes CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2011-11-01 US disclosed
US-20080318874-A1 Novel Cyclohexane Derivative, Prodrug Thereof and Salt Thereof, and Therapeutic Agent Containing the Same for Diabetes CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2008-12-25 US disclosed
EP-1783110-A1 NOVEL CYCLOHEXANE DERIVATIVE, PRODRUG THEREOF AND SALT THEREOF, AND THERAPEUTIC AGENT CONTAINING THE SAME FOR DIABETES CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2007-05-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080318874-A1 Novel Cyclohexane Derivative, Prodrug Thereof and Salt Thereof, and Therapeutic Agent Containing the Same for Diabetes SLC5A1, GPR119, SLC5A2 ALDH5A1 635/4885ABAT 829/4885EGFR 3331/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.